A Look Into Healthcare Sector Value Stocks
What are Value Stocks?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.
Below is a list of notable value stocks in the healthcare sector:
Morphic Holding (NASDAQ: MORF) - P/E: 7.1
Supernus Pharmaceuticals (NASDAQ: SUPN) - P/E: 9.23
Plus Therapeutics (NASDAQ: PSTV) - P/E: 0.3
Ocugen (NASDAQ: OCGN) - P/E: 0.05
Seneca Biopharma (NASDAQ: SNCA) - P/E: 8.9
Most recently, Morphic Holding reported earnings per share at -0.52, whereas in Q1 earnings per share sat at -0.55. Morphic Holding does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Supernus Pharmaceuticals has reported Q2 earnings per share at 0.65, which has increased by 62.5% compared to Q1, which was 0.4. Supernus Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Plus Therapeutics has reported Q2 earnings per share at -0.45, which has decreased by 60.71% compared to Q1, which was -0.28. Plus Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Most recently, Ocugen reported earnings per share at -0.19, whereas in Q1 earnings per share sat at -0.07. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Seneca Biopharma saw an increase in earnings per share from -0.24 in Q1 to -0.15 now. Seneca Biopharma does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
